Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Public ClinicalTrials.gov record NCT01008462. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia. Autologous stem cell transplantation uses the patient's stem cells and does not cause graft versus host disease (GVHD) and has a very low risk of death, while minimizing the number of cancer cells. Peripheral blood stem cell (PBSC) transplant uses stem cells from the patient or a donor and may be able to replace immune cells that were destroyed by chemotherapy. These donated stem cells may help destroy cancer cells. Bone marrow transplant known as a nonmyeloablative transplant uses stem cells from a haploidentical family donor. Autologous peripheral blood stem cell transplant followed by donor bone marrow transplant may work better in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia.
Study identification
- NCT ID
- NCT01008462
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 16 participants
Conditions and interventions
Conditions
- B-Cell Prolymphocytic Leukemia
- Hypodiploidy
- Loss of Chromosome 17p
- Plasma Cell Leukemia
- Progression of Multiple Myeloma or Plasma Cell Leukemia
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Non-Hodgkin Lymphoma
- Recurrent Childhood Hodgkin Lymphoma
- Recurrent Childhood Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Plasma Cell Myeloma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Childhood Hodgkin Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Non-Hodgkin Lymphoma
- Refractory Plasma Cell Myeloma
- Refractory Small Lymphocytic Lymphoma
- t(14;16)
- t(4;14)
- T-Cell Prolymphocytic Leukemia
- Waldenstrom Macroglobulinemia
Interventions
- Allogeneic Bone Marrow Transplantation Procedure
- Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Autologous Hematopoietic Stem Cell Transplantation Procedure
- Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation Procedure
- Carmustine Drug
- Cyclophosphamide Drug
- Cytarabine Drug
- Etoposide Drug
- Fludarabine Phosphate Drug
- Laboratory Biomarker Analysis Other
- Melphalan Drug
- Mycophenolate Mofetil Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Tacrolimus Drug
- Total-Body Irradiation Radiation
Procedure · Drug · Other + 1 more
Eligibility (public fields only)
- Age range
- Up to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 17, 2010
- Primary completion
- Jun 29, 2018
- Completion
- Jun 29, 2018
- Last update posted
- Jun 10, 2019
2010 – 2018
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
| Froedtert and the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01008462, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2019 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01008462 live on ClinicalTrials.gov.